A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
Clinical trial NCT00362466 · TERMINATED
Trial details
- NCT number
- NCT00362466
- Sponsor
- Bristol-Myers Squibb
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2007-04-01
- Primary completion
- 2008-06-01
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.